In the BioHarmony Drug Report Database
Infigratinib
Truseltiq (infigratinib) is a small molecule pharmaceutical. Infigratinib was first approved as Truseltiq on 2021-05-28. It is used to treat cholangiocarcinoma in the USA. The pharmaceutical is active against fibroblast growth factor receptor 1, fibroblast growth factor receptor 2, and fibroblast growth factor receptor 3. In addition, it is known to target vascular endothelial growth factor receptor 2 and fibroblast growth factor receptor 4. Truseltiq’s patent is valid until 2034-12-11 (FDA).
Trade Name
|
Truseltiq |
|---|---|
Common Name
|
infigratinib |
ChEMBL ID
|
CHEMBL1852688 |
Indication
|
cholangiocarcinoma |
Drug Class
|
Tyrosine kinase inhibitors |
Image (chem structure or protein)